US6031701013 - MLYS (XNAS)

Mineralys Therapeutics, Inc. - Common Stock Aktie

12,53 USD

1,79 % 0,22 USD 02.01.2025 22:00 - USD - NASDAQ (XNAS) - Aktuelle Kurse und Charts bei MoneyPeak

Aktuelle Kurse von Mineralys Therapeutics, Inc. - Common Stock

Börse	Ticker	Währung	Letzter Umsatz	Kurs	Tagesveränderung	Tagesveränderung %
NASDAQ	MLYS	USD	02.01.2025 22:00	12,53 USD	12,31 USD	1,79 %

Performance

Day	Week	Month	3 Months	6 Months	1 Year	5 Years
0,00 %	-2,26 %	-7,12 %	-2,11 %	3,64 %	44,35 %	-32,05 %

Company Profile for Mineralys Therapeutics, Inc. - Common Stock Share

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Company Data for Mineralys Therapeutics, Inc. - Common Stock Share

Name Mineralys Therapeutics, Inc. - Common Stock

Company Mineralys Therapeutics, Inc.

Symbol MLYS

Website https://mineralystx.com

Primary Exchange

NASDAQ

ISIN US6031701013

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Mr. Jon Congleton

Market Capitalization 596 Mio

Country United States of America

Currency USD

Employees 0,0 T

Address 150 N. Radnor Chester Rd., 19087 Radnor

IPO Date 2023-02-10

Ticker Symbols

Name	Symbol
NASDAQ	MLYS

More Shares

Investors who Mineralys Therapeutics, Inc. - Common Stock hold also have the following shares in their portfolio:

APARTMENT INVESTMENT AND MANAGEMENT CO Share

Dimensional ETF Trust Dimensional International Small Cap ETF ETF

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Jobs Community Feedback Changelog